ATCC

ATCC Expands Leadership Team to Provide Vision and Growth Strategy

Retrieved on: 
Tuesday, July 12, 2022
Science, Public Policy, Government, Other Science, Biotechnology, Research, White House, Federal Government, Health, Infectious Diseases, Linda, Public health, COVID-19, United States Patent and Trademark Office, Friends, Monkeypox, PATH, Master of Business Administration, Leadership, Forest Law Enforcement and Governance Program, Board of directors, University of Nebraska Medical Center, History, JDRF, Drug discovery, CEO, Government, IP, Director, Bradford, Chemistry, Intellectual property, Carey Business School, Invention, Johns Hopkins University, Technology transfer, Doctor of Philosophy, Collection, Intellectual, Business administration, Kantar Group, Negotiation, Research, Growth, Board, University, Patent, Industry, Partnership, AFS, Nebraska Medicine, Management, Pharmaceutical industry, Science, Biotechnology, Biology, ATCC

Both positions will continue to bring leadership and vision to ATCC's growth strategy.

Key Points: 
  • Both positions will continue to bring leadership and vision to ATCC's growth strategy.
  • Since joining the company in 2004, Bradford has been essential to the expansion of AFS's client base and strengthened its infrastructure to support its growth strategy.
  • "My congratulations to Rebecca on her promotion," said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.
  • "Linda is responsible for the revitalization and growth of the Licensing and IP leadership team, responsible for overall strategy, management, and infrastructure," remarked Dr. Cypess.

ATCC Awarded Two Contracts from Gennova Biopharmaceuticals for the Continued Development of Cell Banks to Help Diagnose and Prevent Leishmaniasis

Retrieved on: 
Monday, June 13, 2022
FDA, White House, Federal Government, Stem Cells, University, Pharmaceutical, Education, General Health, Infectious Diseases, Public Policy, Government, Clinical Trials, Biotechnology, Science, Alternative Medicine, Other Science, Research, Health, Science, Human, Vaccination, CL, Throat, Research, Biotechnology, Leishmania major, Infection, LST, Spleen, Food, Nose, McGill, Contract, CEO, Wound, Leishmanin skin test, Leishmania donovani, Liver, Mouth, Government, Disease, GMP, Microbiology, MCB Bank, WCBS, Biting, FDA, Doctor of Philosophy, MCB, VL, CGMP, Industry, Collection, Drug discovery, Public health, Hubli railway division, Ohio State University, Bone marrow, History, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Vaccine, Pharmaceutical industry, Leishmania, Leishmaniasis, ATCC

ATCC will use its recognized expertise in providing critical gold standard reagents to develop Master Cell Banks (MCBs) and Working Cell Banks (WCBs) for the production of a Leishmania donovani diagnostic test and an attenuated Leishmania major vaccine.

Key Points: 
  • ATCC will use its recognized expertise in providing critical gold standard reagents to develop Master Cell Banks (MCBs) and Working Cell Banks (WCBs) for the production of a Leishmania donovani diagnostic test and an attenuated Leishmania major vaccine.
  • Additionally, ATCC will offer cGMP storage of the MCB and safety stock vials at its facility for one year.
  • It is the leading developer and supplier of authenticated cell lines, microorganisms, and associated data for academia, industry, and government.
  • ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland.

ATCC Announces Two Projects from the U.S. Department of Agriculture’s Chief Scientific In-House Research Agency, the Agricultural Research Service

Retrieved on: 
Tuesday, April 12, 2022
White House, Federal Government, Other Science, Pharmaceutical, Research, Oncology, Infectious Diseases, Genetics, Stem Cells, Science, Public Policy, Government, Clinical Trials, General Health, FDA, Biotechnology, Agriculture, Alternative Medicine, Natural Resources, Health, ARS, CEO, PIADC, Government, Federal, Research, Quarantine, Collection, ASFV, Science, Doctor of Philosophy, Drug discovery, Cell, Infection, Global health, Vaccine, African swine fever virus, Solution, History, Gene, Public health, Agricultural Research Service, Immortalised cell line, Industry, United States Department of Agriculture, Senior, CRISPR, Virus, USDA, India–Singapore Comprehensive Economic Cooperation Agreement, ATCC

For the second project, ATCC will create genetically modified cell lines capable of growing and producing African Swine Fever Virus (ASFV) vaccines.

Key Points: 
  • For the second project, ATCC will create genetically modified cell lines capable of growing and producing African Swine Fever Virus (ASFV) vaccines.
  • Through these two projects, we will continue to support the USDA and strive to help the ARS achieve its mission of delivering scientific solutions to national and global agricultural challenges, said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.
  • African Swine Fever is a devastating disease of domestic and feral swine and causes a significant economic impact on the agricultural industry.
  • ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland.

Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate

Retrieved on: 
Thursday, April 7, 2022
Central, T cell, LinkedIn, WHO, Fever, Dengue fever, Public health, Coronavirus, Research, Egg, Prevalence, ATCC, Mosquito-borne disease, MHC, Safety, Infection, Twitter, Climate, Science, Drug discovery, Flaviviridae, CD8, Nociception, History, Collection, Vaccine, Yellow fever, Chikungunya

Emergex has a growing pipeline of innovative CD8+ T-Cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease.

Key Points: 
  • Emergex has a growing pipeline of innovative CD8+ T-Cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease.
  • Other programmes in development include vaccine candidates for universal (pandemic) Influenza, Chikungunya, and a booster vaccine for Yellow Fever.
  • With potential stability at ambient temperatures, the vaccine candidates as intended reduce the burden and logistics of vaccine administration.
  • Yellow Fever is a severe, potentially fatal, mosquito-borne disease endemic to tropical and subtropical regions of Africa, Central and South America.

ATCC Announces Expansion of its Bioinformatics Data Platform with QIAGEN

Retrieved on: 
Monday, April 4, 2022
Research, Technology, Software, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Data Management, Science, Life, Knowledge, Therapy, DNA, Health, Public health, QIAGEN, Biotechnology, Research, Head, Genomics, Cancer, CEO, RNA, Corporate development, Senior, RNA-Seq, Biomedical Research, Database, Protein, Cell, Doctor of Philosophy, WES, Sequence, Science, Drug discovery, Solution, Transcriptome, Blood, History, Collection, Pharmaceutical industry, ATCC

This first-of-its-kind arrangement will allow ATCC to provide data provenance that is traceable, standardized and authenticated to its original source, said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.

Key Points: 
  • This first-of-its-kind arrangement will allow ATCC to provide data provenance that is traceable, standardized and authenticated to its original source, said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.
  • We are embracing this digital biotechnology to be able to share our expertise in advancing authentication to the research community.
  • Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights, tied together in seamless and cost-effective workflows through automation solutions.
  • ATCC is a nonprofit organization with headquarters in Manassas, Virginia, and a research and development innovation center in Gaithersburg, Maryland.

ATCC Announces Award from National Cancer Institute to Provide Cancer Epidemiology Services to the Research Community

Retrieved on: 
Monday, March 28, 2022
Research, Other Health, Pharmaceutical, Oncology, White House, Federal Government, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Public Policy, Government, Other Science, Manu v Steelink Contracting Services Ltd, Company, National Cancer Institute, Public health, IDIQ, Global health, Research, Program, Indefinite, Cancer, CEO, Senior, Laboratory, Doctor of Philosophy, Science, Drug discovery, NCI, National, Division, History, Collection, Pharmaceutical industry, ATCC, Genetics

According to the DCEG website, its mission is to discover the causes of cancer and inform the means for prevention by conducting transdisciplinary epidemiological and genetic research.

Key Points: 
  • According to the DCEG website, its mission is to discover the causes of cancer and inform the means for prevention by conducting transdisciplinary epidemiological and genetic research.
  • The MEAS program provides support services for clinical studies on the genetic and other cellular events that influence the onset of different types of cancer.
  • "At ATCC, we are committed to supporting members of the clinical research community by providing them with the highest quality biomaterials for cancer research," said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.
  • ATCC is a nonprofit organization with headquarters in Manassas, Virginia, and a research and development innovation center in Gaithersburg, Maryland.

ATCC Announces Award from National Institute of Allergy and Infectious Diseases to Develop Well-Characterized Challenge Material of BSL-3 and BSL-4 Viruses

Retrieved on: 
Monday, March 14, 2022
Research, Infectious Diseases, Genetics, Stem Cells, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Virus, National Institute, NIAID, National, Senior, Infection, Collection, Vapour-phase-mediated antimicrobial activity, Research, Public health, Therapy, National Institute of Allergy and Infectious Diseases, Biosafety, Emergency, Science, NIH, WCCM, Drug discovery, Global health, Doctor of Philosophy, Division, History, CEO, BSL-4, Pharmaceutical industry, Vaccine, Microbiology, ATCC

ATCC will provide well-characterized Biosafety Level-3 (BSL-3) and BSL-4 viruses of public health concern, including those of pandemic or epidemic potential, to assist in developing medical countermeasures.

Key Points: 
  • ATCC will provide well-characterized Biosafety Level-3 (BSL-3) and BSL-4 viruses of public health concern, including those of pandemic or epidemic potential, to assist in developing medical countermeasures.
  • ATCC will be contributing to NIAIDs mission of more than six decades to support the development of novel therapeutics and biological inhibitors to combat infectious diseases.
  • Viruses with epidemic or pandemic potential require extensive investigational research toward the development of therapeutics.
  • There is a critical need to improve production capacity while ensuring genomic homogeneity through well-characterized challenge material (WCCM) in therapeutic product development.

Emmy Award-Winning Broadcast Journalist and Storyteller Steve Atkinson Joins The Seismic Collaborative as Vice President of Executive Media Engagement

Retrieved on: 
Friday, March 11, 2022
Biotechnology, Public Relations, Investor Relations, Health, Marketing, Communications, Celebrity, Entertainment, Other Health, Centurion, ABC, Marketing, NBC, Vikki, Melissa, Mentorship, Emmy Awards, Communication, Seismic Experiment for Interior Structure, The Wall Street Journal, Openwave, PR, Health, Multimedia, Athlete, Leadership, IBM, Qualcomm, Hitachi, CBS, Centurion Card, Technology, Chief executive officer, ATCC, Head, Growth, Intelligence, TechCrunch, BD, CEO, Creativity, Management, Entertainment, Public relations, Apple, Seismology, Illumina

View the full release here: https://www.businesswire.com/news/home/20220311005118/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220311005118/en/
    Emmy Award-Winning Broadcast Journalist and Storyteller Steve Atkinson Joins The Seismic Collaborative as Vice President of Executive Media Engagement (Photo: Business Wire)
    Steve Atkinson is an award-winning communications expert who brings more than 30 years of broadcast journalism, storytelling, and public speaking experience to Seismic.
  • As Vice President of Executive Media Engagement, Steve will establish and lead Seismics new Executive Media Engagement practice, where he will be responsible for preparing CEOs and executive teams for impactful media exposure through comprehensive, meticulous and personalized coaching.
  • Steve knows and understands firsthand what members of the media desire when choosing their subjects and how they formulate their stories, said Lisa Rodriguez, CEO of The Seismic Collaborative.
  • For almost eight years, Vikki has brought her signature business intelligence, executive presence, strategic vision, creativity and dispassionate judgment to Seismic.

Ultra Clean Expands Global Footprint with New Facility in Cavan, Ireland, Creating Approximately 100 Jobs

Retrieved on: 
Monday, March 7, 2022
Intel, Science, Investment, Industry, Quality control, Government, Innovation, Solution, ATCC, EMEA, Product, FBI Criminal Justice Information Services Division, Environment, Hilltop Holdings Inc., UCT, Engineering, Service, Enterprise, Nasdaq, Animal, Fine chemical, Renewable energy, Q3, IDA Ireland

This investment represents a key milestone in UCT's global expansion plans supporting surging demand in the semiconductor industry.

Key Points: 
  • This investment represents a key milestone in UCT's global expansion plans supporting surging demand in the semiconductor industry.
  • Cavan, Ireland will be UCT's 15th Services site and will primarily support Intel Corporation and other European-based customers.
  • The project, which will create approximately 100 jobs when fully operational, is supported by the Irish Government through Ireland's inward investment agency, IDA Ireland.
  • Roles at the new facility will include engineering, manufacturing, facilities, on-site shipping and receiving, quality control, sales, and customer service positions.

ATCC Announces Awards from DTRA that Strengthen ATCC’s Antiviral Drug Discovery and Development Portfolio for Global Health and Biodefense

Retrieved on: 
Tuesday, February 15, 2022
Stem Cells, Other Policy Issues, Other Science, FDA, Technology, Research, Homeland Security, Public Policy, Government, Other Health, Pharmaceutical, Infectious Diseases, Genetics, Clinical Trials, Other Technology, Biotechnology, Alternative Medicine, Health, Agriculture, Science, Natural Resources, Transfer, History, Collection, Technology, Mortality, CEO, DTRA, Science, DVM, Global health, AFS, Solution, United States Department of Defense, Defense Threat Reduction Agency, Therapy, Translational research, Virus, Virology, Artificial intelligence, FDA, Partnership, Infection, Public health, Disease, Senior, Machine learning, Research, Drug discovery, Technology transfer, Pharmaceutical industry, MD, ATCC

The work will identify and characterize novel therapeutic approaches to viruses of global health concern.

Key Points: 
  • The work will identify and characterize novel therapeutic approaches to viruses of global health concern.
  • Promising therapeutic candidates will be tested for efficacy with in vitro and in vivo model systems.
  • "ATCC is committed to supporting this global health initiative by providing the novel scientific research and development solutions needed to address these high-morbidity and mortality infectious disease outcomes," said Raymond H. Cypess, DVM, Ph.D., Chairman, and CEO of ATCC.
  • ATCC will also employ ML/AI strategies to integrate the cellular response datasets and identify broad-spectrum therapeutic candidates to combat various pathogens.